TLSA

Tiziana Life Sciences Ltd (TLSA) | Rumor.io

Tiziana Life Sciences

TLSA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,110

Bullish sentiment (50-day avg)97%

Price to earnings ratio-6.16

Market capitalization124.7M

Earnings per share-0.16

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-18.4M

Social

What share of all stock conversation is about TLSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 25

The Phase 2a trial for non-active Secondary Progressive Multiple Sclerosis is complete, with 12-week topline data imminent, and analyst price target of $8.00–$9.18.
The company's Intranasal Foralumab targets microglial activation to stop neurodegeneration where other MS drugs completely fail.
The upcoming data readout is expected to be available to the companies that have expressed an early interest, with some expecting a potential "BOOM or BUST" outcome by the end of October.

Generated by AI

Sentiment

Of the messages about TLSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	33.33% -41.67	88.24% -2.24	91.21% +15.74	64.8% -8.97
Bearish	66.67% +41.67	11.76% +2.24	8.79% -15.74	35.2% +8.97

Bullish· Jan 23

$TLSA is expected to reach $3, potentially seeing a +300% gain.
The company's Foralumab has shown positive results in reducing inflammation in obese patients, with potential for Big Pharma involvement and partnership or acquisition.
Volume is increasing, and the stock is nearing a breakout point, with some expecting a wild reversal at a specific time.

Bearish· Aug 15

$TLSA's market cap is based on a $60 million market value, indicating a potentially unstable financial situation.
Alzheimer's stocks, including $TLSA, tend to be "forgotten quickly", implying a lack of long-term interest or investment.
$TLSA is expected to break a buck ($1) and may experience significant price drops, with some investors aiming to short the stock at low prices.

Generated by AI

Topics

Of the messages about TLSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	47.73%	80%	75.19%
Technical Analysis	—	18.18%	5.29%	8.45%
Controversies	—	0%	0.59%	2.96%
Analysts	—	34.09%	14.12%	1%
Earnings	—	0%	0%	8.63%
Macro	—	0%	0%	3.78%

Announcements· Oct 18

Tiziana Life Sciences Ltd. has announced that the FDA has allowed at-home dosing of its Intranasal Foralumab treatment for multiple sclerosis patients.
Patients in the intermediate size patient population will receive Intranasal Foralumab as part of the at-home dosing initiative, with over a year of safety exposure to anti-CD3 Foralumab showing well-tolerated results.
The at-home dosing of Intranasal Foralumab is expected to improve patient compliance and make innovative therapies more accessible to patients, ultimately improving their quality of life.

Technical Analysis· Feb 9

The 50MA is likely to cross over the 200MA in $TLSA, indicating a potential bullish trend.
The chart of $TLSA is seen as a bullish setup, suggesting a strong upward momentum.
The 1-year chart of $TLSA shows a cup forming, indicating a possible reversal and a potential upward move.

Generated by AI

Community

Of the messages about TLSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	71.49%	69.07%	35.77%
Newcomers	50%	28.51%	30.93%	64.23%

Regulars· Oct 18

Tiziana Life Sciences (TLSA) has received FDA allowance for at-home dosing of its intranasal Foralumab for multiple sclerosis treatment.
The allowance is a significant step forward for Foralumab, a potential treatment for multiple sclerosis.
Tiziana Life Sciences' stock price has increased by 12.3% pre-market following the FDA announcement.

Newcomers· Aug 5

Newcomers are watching Tiziana Life Sciences Ltd for its potential price movement, considering its implied move and open interest in options contracts.
Insider buying activity is being highlighted, with the CEO, Ivor Elrifi, purchasing 667,000 shares at $1.00, increasing his stake in the company.
The company's volume is being noted, with some users commenting on the high volume and price stability, despite not being a penny stock.

Generated by AI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind,...

8d agoYahoo Finance

Tiziana Life Sciences stock jumps on MS trial partnership

12d agoInvesting.com

Why Is Tiziana Life Sciences Stock Gaining Thursday?

12d agoBenzinga

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis...

12d agoYahoo Finance

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing...

26d agoYahoo Finance

BTIG initiates Tiziana Life Sciences stock with buy on MS drug

27d agoInvesting.com

Also Discussed

Investors talking about TLSA also mention

#	Name	Attention
1	OKYO Pharma Ltd.OKYO	0%0
2	ICD - Independence Contract Drilling, Inc.	——
3	VanEck Fabless Semiconductor ETFSMHX	0%0
4	Fidelity D&D Bancorp, Inc.FDBC	0%new
5	Precision BioSciences, Inc.DTIL	0%new
6	Tradr 2X Short TSLA Daily ETFTSLQ	0%0
7	PRVB - Provention Bio, Inc.	——
8	TELA Bio, Inc.TELA	0%0
9	Eastman Kodak CompanyKODK	0%0
10	First Trust Rising Dividend Achievers ETFRDVY	0%new

Tiziana Life Sciences Ltd

Healthcare
Biotechnology

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders. The company is also advancing additional programs, including TZLS-501, an anti-IL-6R antibody aimed at inflammatory pathways, and Milciclib, an oncology candidate evaluated in solid tumors and related cancer indications. Tiziana Life Sciences uses alternative drug delivery approaches, including nasal, oral, and inhalation routes, to support localized immunotherapy and broaden treatment options across autoimmune, inflammatory, and cancer-related markets.

Website

Location

14/15 Conduit Street

London, W1S 2XJ

United Kingdom

Social

What share of all stock conversation is about TLSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 25

The Phase 2a trial for non-active Secondary Progressive Multiple Sclerosis is complete, with 12-week topline data imminent, and analyst price target of $8.00–$9.18.
The company's Intranasal Foralumab targets microglial activation to stop neurodegeneration where other MS drugs completely fail.
The upcoming data readout is expected to be available to the companies that have expressed an early interest, with some expecting a potential "BOOM or BUST" outcome by the end of October.

Generated by AI

Sentiment

Of the messages about TLSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	33.33% -41.67	88.24% -2.24	91.21% +15.74	64.8% -8.97
Bearish	66.67% +41.67	11.76% +2.24	8.79% -15.74	35.2% +8.97

Bullish· Jan 23

$TLSA is expected to reach $3, potentially seeing a +300% gain.
The company's Foralumab has shown positive results in reducing inflammation in obese patients, with potential for Big Pharma involvement and partnership or acquisition.
Volume is increasing, and the stock is nearing a breakout point, with some expecting a wild reversal at a specific time.

Bearish· Aug 15

$TLSA's market cap is based on a $60 million market value, indicating a potentially unstable financial situation.
Alzheimer's stocks, including $TLSA, tend to be "forgotten quickly", implying a lack of long-term interest or investment.
$TLSA is expected to break a buck ($1) and may experience significant price drops, with some investors aiming to short the stock at low prices.

Generated by AI

Topics

Of the messages about TLSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	47.73%	80%	75.19%
Technical Analysis	—	18.18%	5.29%	8.45%
Controversies	—	0%	0.59%	2.96%
Analysts	—	34.09%	14.12%	1%
Earnings	—	0%	0%	8.63%
Macro	—	0%	0%	3.78%

Announcements· Oct 18

Tiziana Life Sciences Ltd. has announced that the FDA has allowed at-home dosing of its Intranasal Foralumab treatment for multiple sclerosis patients.
Patients in the intermediate size patient population will receive Intranasal Foralumab as part of the at-home dosing initiative, with over a year of safety exposure to anti-CD3 Foralumab showing well-tolerated results.
The at-home dosing of Intranasal Foralumab is expected to improve patient compliance and make innovative therapies more accessible to patients, ultimately improving their quality of life.

Technical Analysis· Feb 9

The 50MA is likely to cross over the 200MA in $TLSA, indicating a potential bullish trend.
The chart of $TLSA is seen as a bullish setup, suggesting a strong upward momentum.
The 1-year chart of $TLSA shows a cup forming, indicating a possible reversal and a potential upward move.

Generated by AI

Community

Of the messages about TLSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	71.49%	69.07%	35.77%
Newcomers	50%	28.51%	30.93%	64.23%

Regulars· Oct 18

Tiziana Life Sciences (TLSA) has received FDA allowance for at-home dosing of its intranasal Foralumab for multiple sclerosis treatment.
The allowance is a significant step forward for Foralumab, a potential treatment for multiple sclerosis.
Tiziana Life Sciences' stock price has increased by 12.3% pre-market following the FDA announcement.

Newcomers· Aug 5

Newcomers are watching Tiziana Life Sciences Ltd for its potential price movement, considering its implied move and open interest in options contracts.
Insider buying activity is being highlighted, with the CEO, Ivor Elrifi, purchasing 667,000 shares at $1.00, increasing his stake in the company.
The company's volume is being noted, with some users commenting on the high volume and price stability, despite not being a penny stock.

Generated by AI

Tiziana Life Sciences

Social

Sep 25

Bullish· Jan 23

Bearish· Aug 15

Announcements· Oct 18

Technical Analysis· Feb 9

Regulars· Oct 18

Newcomers· Aug 5

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Tiziana Life Sciences stock jumps on MS trial partnership

Why Is Tiziana Life Sciences Stock Gaining Thursday?

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

BTIG initiates Tiziana Life Sciences stock with buy on MS drug

Also Discussed

Tiziana Life Sciences Ltd

Company Information

Location

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Tiziana Life Sciences stock jumps on MS trial partnership

Why Is Tiziana Life Sciences Stock Gaining Thursday?

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

BTIG initiates Tiziana Life Sciences stock with buy on MS drug

Also Discussed

Social

Sep 25

Bullish· Jan 23

Bearish· Aug 15

Announcements· Oct 18

Technical Analysis· Feb 9

Regulars· Oct 18

Newcomers· Aug 5